Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 290
Rating:

Prof Ralf-Dieter Hofheinz - Uniklinik Mannheim, Mannheim, Germany

Prof Ralf-Dieter Hofheinz speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the results from a randomised, phase II trial chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer.

He describes the trial design, along with the patient population selected and the main hypothesis of the study which was that the pathological complete response rate (pCR) would increase 25% after total neoadjuvant therapy (TNT).

Prof Hofheinz states that the participants that were administered with chemoradiotherapy first, and later consolidation chemotherapy achieved a pCR of 25 percent - compared to patients who received chemotherapy first, who achieved 17 percent pCR.

He concludes by discussing the upcoming phase III trial, where neoadjuvant chemotherapy will be compared with immediate surgery, in a low-risk patient population.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation